However, compared to the control group, the use of SGLT2 inhibitors in diabetic patients did not show an effect in reducing the risk of MI (RR 0.92; 95% CI: 0.84–1.01; p for heterogeneity 0.49; I2 = 0%; p = 0.09) or stroke (RR 1.08; 95% CI: 0.95–1.23; p for heterogeneity 0.47; I2 = 0%; p = 0.26) (Figure 5). This evidence concerns the gene SLC5A2 and Stroke.